Consequently, fimasartan ameliorates nonalcoholic fatty liver disease mainly through the activation of oxidative metabolism represented by PPARδ-AMPK-PGC-1α pathway. Here, PPARD is linked to metabolic dysfunction-associated steatotic liver disease.